Peptides: The Science, Uses & Safety | Dr. Abud Bakri
Dr. Abud Bakri, a board-certified internal medicine physician and peptide scientist, breaks down peptide types, sourcing, and safety. He covers BPC-157’s origins and animal data, gray-market and compounding risks, angiogenesis concerns, thymic and longevity peptides like epithalon and pinealon, and GLP-1s and GH-related therapies. Short, clear, and grounded discussion of where evidence ends and uncertainty begins.
Top snips
Peptides: Two key categories
4:21 – 6:24
Peptides = one of the body’s communication languages. Dr. Abud Bakri frames them into two clinical categories:
- Known‑receptor peptides (GLP‑1s like Ozempic, Mounjaro) → predictable, strong clinical effects.
- No‑known‑receptor / epigenetic peptides (BPC‑157, TB‑500, pinealon) → lots of animal data, unclear human mechanisms.
Takeaway: receptor identity → predictability & safety.
— Abud Bakri
BPC‑157: gut peptide with big hype
6:38 – 44:57
BPC‑157 is a 15‑amino‑acid fragment derived from gastric protein. In animals it accelerates tendon, nerve, and gut healing, and even reduced alcohol withdrawal in mice.
Caveats: most data come from one group, only tiny human trials (rectal enemas), and we don’t fully know if oral BPC goes systemic.
Concern: stimulates VEGF/angiogenesis — theoretical tumor growth risk.
— Abud Bakri
Sourcing & safety: gray market vs compounders 🇨🇳
35:29 – 38:36
Peptide APIs almost always come from China. Routes matter:
- Big pharma: highest QC.
- Compounding pharmacies: variable — some excellent, some poor.
- Gray/black market: inconsistent identity, batch‑to‑batch risk, contamination possible.
Regulatory nuance: BPC‑157 moved between compounding categories; state medical boards differ. Best practice: work with an informed clinician and trusted compounder.
— Abud Bakri
Bioregulators: epithalon & pinealon — DNA/clock effects
1:08:35 – 1:24:33
Epithalon and pinealon (EDR) are bioregulators that modulate gene expression and circadian machinery.
Russian data suggest they can restore melatonin rhythms, improve cognitive/stress resilience, and showed lower mortality in long‑term nursing‑home studies.
Caveat: mostly Soviet/Russian literature, limited modern randomized human trials — promising but needs rigorous replication.
— Abud Bakri
Thymus peptides & immunity: thymosin‑α1, TB‑500
1:29:45 – 2:00:45
The thymus trains T cells and shrinks after puberty. Thymic peptides like thymosin‑α1 and TB‑500 can boost T‑cell development and immune function.
Signals: small studies and approvals abroad (e.g., adjuvant use), and imaging/lymphocyte ratios can track response.
Practical: monitor CBC (lymphocyte:monocyte ratio) and consult clinicians — evidence promising but incomplete.
— Abud Bakri
GLP‑1s & the ‘Trinity stack’ — benefits vs unknowns
2:13:34 – 2:14:52
GLP‑1s (semaglutide, tirzepatide, retatrutide) deliver 10–30% weight loss and reshape metabolic disease care.
A rising trend: people combine GLP‑1s with growth‑hormone secretagogues and immune peptides — the so‑called “Trinity stack.”
Caveats: long‑term effects on brain development, fertility, and neuroplasticity are not yet well studied. Titrate slowly and work with a clinician.
— Abud Bakri